股份解除质押的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-090 广州迈普再生医学科技股份有限公司 （二）股东股份累计质押情况 截至本公告披露日，上述股东及其一致行动人所持质押股份情况 （一）股东股份解除质押基本情况 股东名称 是否为控股 股东或第一 大股东及其 一致行为人 本次解除 质押数量 （股） 占其所 持股份 比例（%） 占公司 总股本 比例（%） 质押起 始日 质押到期 日期 质权人 袁玉宇 是 1,040,000 9.39 1.55 2024-12 -02 2025-11- 18 深圳市高新投小 额贷款有限公司 如下： 股东名称 持股数 量(股) 持股 比例 本次解 除质押 本次解 除质押 占其 所持 占公 司总 已质押股份情况 未质押股份情 况 股份解除质押的公告 | （%） | 前质押 | 后累计 | 股份 | 股本 | 已质押股 | 占已 | 未质押 | 占未 | 股份数 | 质押股 | 比例 | 比例 | 份限售和 | 质押 | 股份限 | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | - ...

Group 1 - The core viewpoint of the news is that Maipu Medical has shown a significant increase in stock price and trading volume, indicating strong market interest and activity [1] - As of November 14, Maipu Medical's financing balance reached 68.63 million yuan, accounting for 1.45% of its market capitalization, which is above the 80th percentile of the past year [1] - The company reported a net financing outflow of 1.41 million yuan on November 14, with a total financing buy of 3.33 million yuan and a repayment of 4.73 million yuan [1] Group 2 - For the period from January to September 2025, Maipu Medical achieved operating revenue of 249 million yuan, representing a year-on-year growth of 30.53% [2] - The net profit attributable to the parent company for the same period was 75.85 million yuan, reflecting a year-on-year increase of 43.65% [2] - The number of shareholders decreased by 2.36% to 6,043, while the average circulating shares per person increased by 2.52% to 9,272 shares [2] Group 3 - Since its A-share listing, Maipu Medical has distributed a total of 85.80 million yuan in dividends, with 79.20 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders saw a change, with Southern Medicine Health Flexible Allocation Mixed A (000452) exiting the list [3]

Core Points - The Shanghai Composite Index is at 4017.68 points, above the six-month moving average, with a slight decline of 0.29% [1] - A total trading volume of A-shares reached 15648.48 billion yuan today [1] - 113 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The top three stocks with the highest deviation rates from the six-month moving average are: - Electric Investment and Financing (9.07%) - Jie Rong Technology (7.54%) - Annie Shares (4.91%) [1] - Other stocks with smaller deviation rates that have just crossed the six-month line include: - Baoland, Zhongnong Lihua, and Subote [1] Trading Data - The trading performance of selected stocks includes: - Electric Investment and Financing: +9.94% with a turnover rate of 2.09% - Jie Rong Technology: +10.00% with a turnover rate of 8.20% - Annie Shares: +6.44% with a turnover rate of 18.47% [1] - Additional stocks with notable performance include: - Yahua Electronics: +6.29% - Zhonglu Shares: +7.08% - Jinlihua Electric: +4.81% [1]

Core Points - The company, Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., announced that its actual controller and major shareholder, Mr. Yuan Yuyu, has pledged part of his shares [2] Summary by Category - **Share Pledge Details** - The number of shares pledged is 2,600,000 [2]

Core Points - The company Maipu Medical announced the resignation of independent director Yuan Qing due to personal work commitments, which hindered his ability to fulfill his duties [2] Group 1 - The board of Maipu Medical received a written resignation report from independent director Yuan Qing on November 12, 2025 [2] - Yuan Qing will no longer hold any positions within the company or its subsidiaries after his resignation [2] - He served as the chairman of the audit committee and a member of the compensation and assessment committee [2]

Group 1 - The company, MaiPu Medical, announced plans to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd. through a combination of issuing shares and cash payments [2] - The acquisition involves 10 transaction parties, including Guangzhou Zexin Medical Technology Co., Ltd. and Guangzhou Yichuangxiang Investment Partnership (Limited Partnership) [2] - The Shenzhen Stock Exchange has accepted the application for the asset purchase and fundraising, confirming that the application documents are complete and in legal form [2]

Group 1 - The core point of the article is that MaiPu Medical has announced significant share pledges by its executive, indicating potential liquidity concerns [1] - As of the announcement date, Yuan Yuyu has pledged a total of 8.08 million shares, which represents 72.92% of his total holdings [1] - For the fiscal year 2024, MaiPu Medical's revenue composition is heavily weighted towards implantable medical devices, accounting for 97.51% of total revenue, with other sources contributing only 2.49% [1] Group 2 - The current market capitalization of MaiPu Medical is reported to be 4.6 billion yuan [2]

股份质押的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-089 广州迈普再生医学科技股份有限公司 关于公司实际控制人、控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）近日 接到公司实际控制人、控股股东袁玉宇先生的函告，获悉其所持有的 公司部分股份办理了质押登记手续，具体情况如下： 注：1、上述质押股份不负担重大资产重组等业绩补偿义务； 2、本公告中的无限售条件流通股包括高管锁定股，不存在股份 冻结情形，下同； 3、公司目前总股本为 67,049,620 股（含回购股份）。 （二）实际控制人、控股股东股份累计质押情况 股东名 称 是否为控 股股东或 第一大股 东及其一 致行动人 本次质 押数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 是否 为限 售股 是否 为补 充质 押 质押 起始 日 质押到期 日期 质权人 质押 用途 袁玉宇 是 2,600, 000 23.46 3.88 否 否 2025- 11-1 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Insights - The company reported a revenue of 249 million yuan for the first three quarters of 2025, representing a year-on-year growth of 30.53%. The net profit attributable to the parent company was 76 million yuan, up 43.65% year-on-year [5] - The company plans to acquire 100% of Easy Medical for 335 million yuan, which is expected to broaden its market potential [6] - The company has secured exclusive agency agreements for various medical products, which are anticipated to enhance revenue and profit further [7] Financial Performance - For Q3 2025, the company achieved a revenue of 91 million yuan, a 32.74% increase year-on-year, with a net profit of 29 million yuan, reflecting a 39.89% growth [5] - The projected revenues for 2025-2027 are 364 million yuan, 503 million yuan, and 701 million yuan, with corresponding year-on-year growth rates of 30.7%, 38.2%, and 39.4% respectively [8] - The net profit attributable to the parent company is expected to be 108 million yuan, 152 million yuan, and 217 million yuan for 2025-2027, with growth rates of 36.7%, 41.3%, and 42.7% respectively [8] Valuation Metrics - The projected P/E ratios for 2025-2027 are 43x, 30x, and 21x, with PEG ratios of 1.17, 0.74, and 0.50 respectively [8]

独立董事离任的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-088 广州迈普再生医学科技股份有限公司 关于公司独立董事离任的公告 二、备查文件 袁庆先生的请辞报告。 特此公告。 一、独立董事离任情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）董事 会于 2025 年 11 月 12 日收到公司独立董事袁庆先生提交的书面请辞 报告。袁庆先生因个人所从事工作岗位的要求，已难以确保投入足够 的时间和精力履行独立董事职责，申请辞去公司第三届董事会独立董 事、审计委员会召集人、薪酬与考核委员会委员职务，离任后不再担 任公司及控股子公司的任何职务。袁庆先生原定的任职期间为 2024 年 5 月 10 日至 2027 年 5 月 9 日。 鉴于袁庆先生离任将导致公司独立董事人数低于董事会成员人 数的三分之一，独立董事中缺少会计专业人士，且相关董事会专门委 员会中独立董事所占比例不符合规定，根据《上市公司独立董事管理 办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》《公司章程》等有关规定，袁庆先生的离任将在公 司股东会选举产生新任具备会计专业背景的独立董事后 ...